Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in 1980-2006 in France
2011

Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in France

Sample size: 1895 publication 10 minutes Evidence: high

Author Information

Author(s): Duong Tu Anh, Sbidian Emilie, Valeyrie-Allanore Laurence, Vialette Cédric, Ferkal Salah, Hadj-Rabia Smaïl, Glorion Christophe, Lyonnet Stanislas, Zerah Michel, Kemlin Isabelle, Rodriguez Diana, Bastuji-Garin Sylvie, Wolkenstein Pierre

Primary Institution: AP-HP, Hôpital Henri-Mondor, Service de Dermatologie, Créteil, France

Hypothesis

What is the mortality rate among patients with Neurofibromatosis 1 (NF1) in France?

Conclusion

The study found significantly increased mortality rates in NF1 patients compared to the general population, particularly in younger age groups.

Supporting Evidence

  • Overall mortality was significantly increased in the NF1 cohort with a standardized mortality ratio (SMR) of 2.02.
  • Excess mortality was particularly high in patients aged 10 to 20 years with an SMR of 5.2.
  • Malignant nerve sheath tumors were the leading cause of death, accounting for 60% of fatalities.
  • Females aged 10 to 20 years had a significantly higher SMR of 12.6 compared to males.
  • Mortality rates were significantly higher in both males and females across various age groups.

Takeaway

Kids and young adults with a condition called Neurofibromatosis 1 are more likely to die earlier than other kids, especially girls.

Methodology

The study included consecutive NF1 patients referred to the National French Referral Center for Neurofibromatoses and calculated standardized mortality ratios (SMRs) based on observed and expected deaths.

Potential Biases

Hospital-based recruitment may overestimate mortality rates as it could favor patients with more severe forms of NF1.

Limitations

The study's retrospective design and hospital-based recruitment may have led to survivorship bias and information bias due to unknown vital status for some patients.

Participant Demographics

Median age at inclusion was 17.7 years, with 44.8% of patients younger than 18 years.

Statistical Information

P-Value

< 10-4

Confidence Interval

1.6-2.6

Statistical Significance

p < 10-4

Digital Object Identifier (DOI)

10.1186/1750-1172-6-18

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication